Design Therapeutics, Inc. is a pioneering biopharmaceutical firm focused on crafting treatments for genetic disorders caused by nucleotide repeat expansions. With a keen eye on diseases like Friedreich Ataxia and Myotonic Dystrophy Type-1, the company is advancing its GeneTAC product candidates to address a range of conditions including Fragile X syndrome and Huntington disease. Founded in 2017 and based in Carlsbad, California, Design Therapeutics aims to transform the lives of patients suffering from these progressive diseases.
An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very…
Pre-Market Stock Futures: The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA | NVDA Price Prediction) blew out its fiscal third-quarter results and offered strong forward guidance, though perhaps not as…
